Business Description

OncoCyte Corp logo
OncoCyte Corp
NAICS : 541380 SIC : 8734
ISIN : US68235C2061
Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Name Current Vs Industry Vs History
Cash-To-Debt 1.67
Equity-to-Asset 0.16
Debt-to-Equity 0.29
Debt-to-EBITDA -0.13
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -7.39
Distress
Grey
Safe
Beneish M-Score -4.05
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 26.22
9-Day RSI 34.99
14-Day RSI 41.17
6-1 Month Momentum % -22.37
12-1 Month Momentum % -34.28

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.78
Quick Ratio 0.78
Cash Ratio 0.67
Days Sales Outstanding 324.54
Days Payable 357

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -33.7
Shareholder Yield % -35.67

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 22.07
Operating Margin % -1590.38
Net Margin % -2890.23
FCF Margin % -1366.06
ROE % -132.13
ROA % -50.21
ROIC % -31.21
ROC (Joel Greenblatt) % -415.71
ROCE % -38.77

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 16.43
PB Ratio 1.97
EV-to-EBIT -1.25
EV-to-EBITDA -1.32
EV-to-Revenue 25.07
EV-to-FCF -1.84
Earnings Yield (Greenblatt) % -80
FCF Yield % -51.18

Financials (Next Earnings Date:2024-08-09 Est.)

LTS:0KCC's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

OncoCyte Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1.382
EPS (TTM) ($) -5.08
Beta -0.65
Volatility % 57.18
14-Day RSI 41.17
14-Day ATR ($) 0.034418
20-Day SMA ($) 2.713485
12-1 Month Momentum % -34.28
52-Week Range ($) 2.31513 - 4.98
Shares Outstanding (Mil) 13.36

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

OncoCyte Corp Filings

Filing Date Document Date Form
No Filing Data

OncoCyte Corp Stock Events

Financials Calendars
Event Date Price($)
No Event Data

OncoCyte Corp Frequently Asked Questions

What is OncoCyte Corp(LTS:0KCC)'s stock price today?
The current price of LTS:0KCC is $2.63. The 52 week high of LTS:0KCC is $4.98 and 52 week low is $2.32.
When is next earnings date of OncoCyte Corp(LTS:0KCC)?
The next earnings date of OncoCyte Corp(LTS:0KCC) is 2024-08-09 Est..
Does OncoCyte Corp(LTS:0KCC) pay dividends? If so, how much?
OncoCyte Corp(LTS:0KCC) does not pay dividend.

Press Release

Subject Date
No Press Release